{
  "docId": "019de076-b731-71da-a78f-007719e300bb",
  "docSlug": "1616e8b22ac58e7f024f1153201d610f",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 42 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-01-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 6,
  "pageCount": 42,
  "prevPage": 5,
  "nextPage": 7,
  "slideType": "timeline",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a timeline to connect corporate strategy to specific clinical trial milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-b731-71da-a78f-007719e300bb/6",
  "deckHref": "/decks/019de076-b731-71da-a78f-007719e300bb",
  "deckJsonHref": "/decks/019de076-b731-71da-a78f-007719e300bb.json",
  "deckAnchorHref": "/decks/019de076-b731-71da-a78f-007719e300bb#slide-6",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.45,
        "x": 0.16,
        "y": 0.43
      },
      "kind": "diagram",
      "text": "2024: EXECUTE ON GLOBAL REGISTRATIONAL STRATEGIES; 2025: FIRST PIVOTAL DATA; 2026: FIRST APPROVED PRODUCT",
      "attrs": null,
      "subkind": "timeline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "22331d08-b02f-46bf-8a42-6d9c2be93f53",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.45,
        "w": 0.26,
        "x": 0.71,
        "y": 0.21
      },
      "kind": "list",
      "text": "Anticipated 2024 Milestones: Progress ARROS-1 Phase 2 with registrational intent; Initiate ALKOVE-1 Phase 2 with registrational intent; Launch 1L ALK strategy; Interim Ph 1/2 data for both ROS1 and ALK programs; Initiate Phase 1 trial for HER2 program",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ad639b2d-cd84-4cbb-a213-99e418582113",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.23,
        "y": 0.77
      },
      "kind": "paragraph",
      "text": "MISSION: Bringing new, potential best-in-class medicines to patients with cancer",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "046338fa-a38a-4fe3-9ec4-faa6d10a8609",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.43,
        "x": 0.055,
        "y": 0.12
      },
      "kind": "title",
      "text": "OnTarget 2026: The Path to Patient Impact",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "98edcfa7-6821-4232-9925-4fa0ef1dc7bc",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Three horizons (McKinsey)",
      "slug": "three-horizons",
      "agent": null,
      "layer": "slide",
      "matchId": "fa425e46-de09-4d7e-88c2-ea7940bcc6e3",
      "evidence": "2024: EXECUTE ON GLOBAL REGISTRATIONAL STRATEGIES; 2025: FIRST PIVOTAL DATA; 2026: FIRST APPROVED PRODUCT",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "timeline",
      "slug": null,
      "matchId": "510c84ff-9a1d-4e50-8da8-2dafa80f137b",
      "evidence": "Visual progression of goals over 2024-2026",
      "confidence": 1
    }
  ],
  "arcBeats": [
    {
      "to": 10,
      "from": 4,
      "beatId": "1b4ba678-72a5-41ab-80a1-d0e9467146f7",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Solution",
      "beatSlug": "sequoia-pitch-solution",
      "evidence": "The deck presents Nuvalent's approach as a potential solution to the problem.",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}